Clinical Trial Update: Open-Label Psilocybin Study in Transdiagnostic Population [Phase 1]

View source ↗

Summary

Open-label Phase 1 trial of psilocybin in a transdiagnostic population. The study targets major depressive disorder, anxiety disorders, post-traumatic stress di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Major Depressive Disorder
• Obsessive-compulsive Disorder
• Post-traumatic Stress Disorder
• Substance Use Disorder

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Yale University | Conditions: Transdiagnostic, Depression - Major Depressive Disorder | Phase 1 | Status: RECRUITING